Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.
Favorable factor
Gastric cancer
Helicobacter pylori
Immune checkpoint inhibitor therapy
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
29
03
2021
accepted:
21
04
2021
pubmed:
30
4
2021
medline:
3
2
2022
entrez:
29
4
2021
Statut:
ppublish
Résumé
Gastric cancer (GC) has the third highest rate of cancer incidence and mortality worldwide. First-line immune checkpoint inhibitor (ICI) therapy for advanced GC led to landmark breakthroughs, but which GC patients are most likely to benefit from ICI therapy needs to be investigated in depth and identified via valuable biomarkers. In this letter, we describe superior outcomes in Asian patients than in North American and European patients treated with ICI therapy, and we speculate that positive H. pylori status may be a beneficial prognostic factor for ICI therapy in patients with GC. Many studies have revealed that H. pylori-activated immune responses improve prognosis in patients with GC via increased PD-L1 expression and CD3
Identifiants
pubmed: 33913072
doi: 10.1007/s10637-021-01122-5
pii: 10.1007/s10637-021-01122-5
doi:
Substances chimiques
CD3 Complex
0
Hedgehog Proteins
0
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1436-1438Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
National Comprehensive Cancer Network (2019) NCCN clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. Version 1. Accessed 31 Mar 2018. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991–4997. https://doi.org/10.1200/JCO.2006.06.8429
doi: 10.1200/JCO.2006.06.8429
pubmed: 17075117
Shitara K, Van Cutsem E, Bang Y-J et al (2020) Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.3370 (published online Sept 3)
doi: 10.1001/jamaoncol.2020.3370
pubmed: 32880601
pmcid: 7489405
Tabernero J, Van Cutsem E, Bang Y-J et al (2019) Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. JCO 37:LBA4007–LBA4007
doi: 10.1200/JCO.2019.37.18_suppl.LBA4007
Eusebi LH, Zagari RM, Bazzoli F (2014) Epidemiology of helicobacter pylori infection helicobacter 19:1–5
pubmed: 25167938
Holokai L, Chakrabarti J, Broda T et al (2019) Increased programmed death-ligand 1 is an early epithelial cell response to helicobacter pylori infection. PLoS Pathog 15(1):e1007468. https://doi.org/10.1371/journal.ppat.1007468
doi: 10.1371/journal.ppat.1007468
pubmed: 30703170
pmcid: 6380601
Xue L-J, Mao X-B, Liu X-B et al (2019) Activation of CD3
doi: 10.1080/15384047.2019.1579957